FilingSEC EDGAR8-K
Edesa Biotech Receives FDA Clearance for Phase 2 Study of EB06 in Vitiligo
· SEC accepted
StagePhase 2
Filing content
Edesa Biotech announced that the FDA cleared its IND application for a Phase 2 clinical study of EB06 in vitiligo, allowing the company to expand recruitment to the U.S.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…